-
Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each
Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.
-
Soleno withdraws EU marketing application for VIOKAT (PWS hyperphagia)
Voluntarily withdrew MAA for VIOKAT (diazoxide choline) from EMA for Prader-Willi syndrome hyperphagia.
-
Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction
Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.
-
Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness
Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.
-
Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch
FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.
-
Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable
Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.
-
Soleno initiates $100M accelerated share repurchase; amends loan facility
Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
-
Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M
Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.
-
Soleno reports death of VYKAT XR patient; company says not drug-related
A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.
-
Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M
Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).
-
Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization
Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.
-
Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M
Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.
-
Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers
VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.
-
FDA approves Soleno's VYKAT XR for hyperphagia in Prader-Willi syndrome
VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in PWS; for ages 4+.
-
Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025
Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.
-
Soleno Therapeutics secures up to $200M debt financing from Oxford Finance; initial $50M drawn
Initial $50 million draw at closing; up to $100 million in milestone tranches tied to FDA approval of DCCR for PWS.
-
FDA extends PDUFA date for Soleno's DCCR NDA to March 27, 2025
FDA extended review period by three months from Dec 27, 2024, to March 27, 2025.
-
Soleno Therapeutics Q3 net loss $76.6M; NDA for DCCR in PWS accepted with Priority Review, PDUFA Dec 27, 2024
NDA for DCCR (diazoxide choline) for Prader-Willi syndrome accepted by FDA with Priority Review; PDUFA target action date December 27, 2024.
-
Soleno Therapeutics board changes: Chairman Mario resigns for health; Dawn Bir appointed as director
Chairman Ernest Mario resigns effective August 15, 2024 for health reasons; no disagreement with company.
-
Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA
NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.
-
Soleno Therapeutics enters $150M at-the-market equity offering with Jefferies
Soleno may sell up to $150M of common stock from time to time under Sale Agreement with Jefferies.
-
Soleno submits NDA to FDA for DCCR to treat Prader-Willi Syndrome
NDA submitted for DCCR (diazoxide choline) extended-release tablets for PWS in patients aged 4+ with hyperphagia.
-
Soleno Q1 net loss $21.4M; FDA breakthrough therapy for DCCR; NDA mid-2024
Net loss of $21.4M ($0.59 per share) vs $8.4M loss in Q1 2023; R&D expense rose to $14.6M from $5.3M.
-
Soleno Therapeutics prices $138M public offering of 3M shares at $46/share
Public offering of 3,000,000 shares at $46.00 per share for gross proceeds of ~$138M.
-
Soleno gets FDA Breakthrough Therapy Designation for DCCR in Prader-Willi Syndrome
FDA grants Breakthrough Therapy Designation for DCCR (diazoxide choline) in adults/children ≥4 yrs with PWS and hyperphagia.
-
Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024
Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.
-
Soleno prices $120M combined public offering and private placement of common stock and pre-funded warrants
Public offering of 3M shares at $20/share, gross ~$60M; underwriter option exercised for 450k additional shares.
-
Soleno reports positive Phase 3 results for DCCR in Prader-Willi; primary endpoint met (p=0.0022)
Primary endpoint: HQ-CT total score difference of 5.0 at week 16 (p=0.0022) favoring DCCR over placebo.
-
Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M
Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
-
Soleno completes PWS trial enrollment, gets $10M; Q1 net loss $8.4M
Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
-
Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion
Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
-
Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update
Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.